 Cabaletta Bio, Inc. is a clinical-stage biotechnology company aiming to develop engineered T-cell therapies for B-cell-mediated autoimmune diseases. Cabaletta has 3 potential therapeutics from its therapeutic platform of autologous autoantibody receptor T Cells for autoimmune diseases with its lead Phase 1 therapeutic, DSG3-CAART, aiming to treat mucosal pemphigus Vulgaris MPV. 